<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-196 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-196</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-196</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-11.html">extraction-schema-11</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or tested mechanisms linking thymoma (thymic epithelial tumors) to autoimmune disease, including defects in thymic negative selection/central tolerance, altered thymic antigen presentation (e.g., AIRE/Fezf2), abnormal thymopoiesis and T-cell repertoire, regulatory T-cell changes, B-cell/antibody phenomena, and clinical/experimental evidence that supports or contradicts these mechanisms.</div>
                <p><strong>Paper ID:</strong> paper-c91f9c7d11112780f9aaf38a9bab1a6bbc743f24</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/c91f9c7d11112780f9aaf38a9bab1a6bbc743f24" target="_blank">A case report on incidental finding of thymoma as anterior mediastinal mass</a></p>
                <p><strong>Paper Venue:</strong> International Journal of Basic & Clinical Pharmacology</p>
                <p><strong>Paper TL;DR:</strong> Thymus is an anterior mediastinal lymphoid organ that is mainly composed of epithelial cells in the outer cortex, myoid cells and lymphocytes in the germinal centre that is responsible for the processing and maturation of T-lymphocytes.</p>
                <p><strong>Paper Abstract:</strong> Thymomas are rare tumors in the anterior mediastinum, representing 50% of anterior mediastinal masses and about 20-30% of all mediastinal tumors. They are of unknown etiology; about 50% of patients with thymomas are diagnosed incidentally with chest radiography. Thymoma is classified into different stages, which determine the prognosis and type of management, the standard primary treatment for these tumors is Thymectomy. We present a case of 55-year female presented with shortness of breath, cough with expectoration and fever for past ten days. Chest x-ray revealed mediastinal widening. CECT chest showed a well-circumscribed heterogeneous solid enhancing mass lesion. FNAC was planned that showed features in favour of thymoma. Biopsy was done that confirmed lymphocyte rich type B thymoma.</p>
                <p><strong>Cost:</strong> 0.009</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e196.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e196.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or tested mechanisms linking thymoma (thymic epithelial tumors) to autoimmune disease, including defects in thymic negative selection/central tolerance, altered thymic antigen presentation (e.g., AIRE/Fezf2), abnormal thymopoiesis and T-cell repertoire, regulatory T-cell changes, B-cell/antibody phenomena, and clinical/experimental evidence that supports or contradicts these mechanisms.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Thymoma-autoimmunity (case report)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Mentions of thymoma-associated autoimmunity and potential mechanisms in this case report</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A single-case clinical report of an incidental, lymphocyte-rich WHO type B thymoma that only briefly references known autoimmune/paraneoplastic associations from the literature (e.g., myasthenia gravis, mucocutaneous disease, hypogammaglobulinemia) but performs no mechanistic or immunologic experiments.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>A case report on incidental finding of thymoma as anterior mediastinal mass</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>thymoma_subtype_and_stage</strong></td>
                            <td>Reported in this case as a lymphocyte-rich type B thymoma (biopsy-confirmed); Masaoka-Koga stage not reported and no further histologic subclass detail provided.</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_phenotype</strong></td>
                            <td>The paper itself reports no autoimmune manifestations in the presented patient. In references cited by the paper, associated autoimmune/paraneoplastic syndromes mentioned include myasthenia gravis (referenced via epidemiology citation), keratoconjunctivitis and lichen planus, hypogammaglobulinemia and absent circulating B cells (Hon et al. case report). The present case did not report co-occurring autoimmune disease.</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmunity_frequency_and_risk_estimates</strong></td>
                            <td>No prevalence, incidence, odds ratios, hazard ratios, or quantitative risk estimates are provided in this paper; only general statements and literature citations are given (no denominators or cohort figures).</td>
                        </tr>
                        <tr>
                            <td><strong>central_tolerance_defect_evidence</strong></td>
                            <td>No direct evidence is presented. The paper does not report assays of thymic medullary function, AIRE or FEZF2 expression, tissue-restricted antigen expression, MHC or antigen-presenting machinery, or related molecular/ IHC / RNA measurements.</td>
                        </tr>
                        <tr>
                            <td><strong>thymocyte_selection_and_T_cell_repertoire_findings</strong></td>
                            <td>Not investigated or reported. No flow cytometry, TCR repertoire sequencing, or data on recent thymic emigrants, CD4/CD8 ratios, clonality, or autoreactive T-cell export are provided.</td>
                        </tr>
                        <tr>
                            <td><strong>regulatory_T_cell_findings</strong></td>
                            <td>Not reported. The study includes no quantification or functional assays of FOXP3+ Tregs, suppressive capacity, or related markers.</td>
                        </tr>
                        <tr>
                            <td><strong>B_cell_and_autoantibody_findings</strong></td>
                            <td>The index case did not report antibody testing or B-cell phenotyping. The references include a cited case report (Hon et al.) of thymoma associated with hypogammaglobulinemia and absent circulating B cells; no autoantibody panels (e.g., AChR, titin) are reported in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>Good_syndrome_and_immunodeficiency_features</strong></td>
                            <td>The paper cites literature (Hon et al.) describing hypogammaglobulinemia and absent circulating B cells in association with thymoma (features consistent with Good syndrome) but does not diagnose or present Good syndrome in the reported patient.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_microenvironment_and_cytokine_signals</strong></td>
                            <td>Not addressed. No data or discussion on cytokines, chemokines, checkpoint molecules, or epithelial cell signalling within the tumor microenvironment are provided.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_and_molecular_associations</strong></td>
                            <td>Not addressed. The paper contains no molecular/genetic profiling, HLA association data, somatic mutation/copy-number information, or epigenetic analysis.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_correlates_and_temporality</strong></td>
                            <td>The case is an incidental radiographic finding in a 55-year-old female; no autoimmune symptoms preceded or followed diagnosis in this report. The paper states thymoma is often diagnosed incidentally in â‰ˆ50% of patients (general background) and notes thymectomy is the standard primary treatment, but gives no data on timing of autoimmunity relative to tumor diagnosis or the effect of thymectomy on autoimmune manifestations.</td>
                        </tr>
                        <tr>
                            <td><strong>interventions_and_response_patterns</strong></td>
                            <td>Treatment mentioned generically is thymectomy as standard primary treatment for thymomas, but the paper provides no data on how autoimmune syndromes responded to thymectomy, immunosuppression, IVIG, plasmapheresis, rituximab, or other therapies.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanistic_hypotheses_proposed</strong></td>
                            <td>The authors do not propose or test specific mechanisms linking thymoma to autoimmunity in this report; only background references to known associations are provided without causal hypotheses.</td>
                        </tr>
                        <tr>
                            <td><strong>key_supporting_results</strong></td>
                            <td>No experimental or quantitative results relevant to autoimmune mechanisms are presented in this paper beyond the clinical pathology confirmation of a lymphocyte-rich type B thymoma in a single patient.</td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_and_alternative_explanations</strong></td>
                            <td>The paper does not present counterevidence or alternative mechanistic explanations; it is a clinical case report focused on diagnosis and histology with literature citations for associated syndromes.</td>
                        </tr>
                        <tr>
                            <td><strong>study_design_and_population</strong></td>
                            <td>Single-patient case report (N=1): a 55-year-old female with respiratory symptoms prompting chest x-ray and CECT, FNAC suggestive of thymoma and biopsy-confirmed lymphocyte-rich type B thymoma. No control group, no cohort data, and no immunologic assays.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_strength_limitations</strong></td>
                            <td>Major limitations for mechanistic inference: single case, absence of immunologic or molecular assays, no longitudinal follow-up regarding autoimmunity, reliance on literature citations for autoimmune associations, and no statistical or experimental data to support or refute mechanisms.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A case report on incidental finding of thymoma as anterior mediastinal mass', 'publication_date_yy_mm': '2019-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Thymoma associated with keratoconjunctivitis, lichen planus, hypogammaglobinemia, and absent circulating B cells. <em>(Rating: 2)</em></li>
                <li>Thymomas: review of current clinical practice. <em>(Rating: 2)</em></li>
                <li>Epidemiology of thymoma and associated malignancies. <em>(Rating: 1)</em></li>
                <li>The epidemiology of myasthenia gravis. <em>(Rating: 1)</em></li>
                <li>A review of thymic tumors. <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>